Table 1.

Demographic data and phenotypic profile of the P. aeruginosa isolates included in the in vivo and in vitro efficacy studies^a

Isolate no.	Source	Location	MIC (mg/liter)
			CAZ-AVI	CAZ	MER	TZP	CIP	TOB
971	Respiratory	ND	4	16	>32	>256	>32	1.5
22	Respiratory	ND	4	64	16	32	0.25	0.5
AZ37-8	Respiratory	ICU	4	64	8	128	16	1
3607	Burn	Non-ICU	4	64	8	>64	ND	ND
1383	Respiratory	ICU	4	64	4	>64	ND	ND
1384	Respiratory	Non-ICU	4	64	8	>64	ND	ND
856	Respiratory	ND	8	8	>32	>256	>32	32
AZ24-2	Respiratory	ICU	8	32	64	64	16	64
JJ4-32	Respiratory	ICU	8	32	64	16	64	128
JJ4-39	Skin	Non-ICU	8	32	4	128	64	64
1387	Blood	Non-ICU	8	32	>8	>64	ND	ND
JJ2-69	Blood	Non-ICU	8	64	1	256	32	64
JJ8-16	Respiratory	ICU	8	64	2	256	0.5	0.25
1389	Urine	Non-ICU	8	64	>8	>64	ND	ND
AZ28-19	Skin	ICU	8	128	4	256	16	1
1382	Blood	ND	8	128	>8	>64	ND	ND
1386	ND	Non-ICU	8	128	>8	>64	ND	ND
1388	Respiratory	ICU	8	128	>8	>64	ND	ND
968	Respiratory	ND	16	32	>32	16	>32	96
JJ1-29	ND	ND	16	32	>64	32	4	0.5
JJ4-36	Skin	Non-ICU	16	64	32	128	8	0.5
JJ4-84	Skin	Non-ICU	16	64	32	256	16	>128
1394	Respiratory	ICU	16	64	>8	>64	ND	ND
JJ1-25	ND	ND	16	128	32	256	0.5	1
1391	Blood	Non-ICU	16	128	>8	>64	ND	ND
JJ3-9	Blood	Non-ICU	16	>128	32	64	16	1
JJ11-54	Skin	Non-ICU	32	128	8	512	4	0.5
JJ7-6	Other	Non-ICU	32	128	1	4	64	128

^aCAZ-AVI, ceftazidime-avibactam; CAZ, ceftazidime; MER, meropenem; TZP, piperacillin-tazobactam; CIP, ciprofloxacin; TOB, tobramycin; ND, not determined; ICU, intensive care unit.